Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 12Lymphoid 8Myeloid 5Plasma cell 4CNS 2

Conditions

Ganglioneuroblastoma 2Neuroblastoma 1

Interventions

Temozolomide 41Magnetic Resonance Spectroscopy 40Specimen Handling 32Radiotherapy 20Radiation 16Biopsy 15Bevacizumab 13Nivolumab 12X-Rays 10Cyclophosphamide 10Radiosurgery 9Carboplatin 9Nuclear Medicine Department, Hospital 7Ipilimumab 7Cisplatin 7Phantoms, Imaging 6Lomustine 6Irinotecan 6AZD 6244 6Vincristine 5Topotecan 5Surgical Procedures, Operative 5Etoposide 5CTLA-4 Antigen 5trametinib 4erdafitinib 4Watchful Waiting 4Surveys and Questionnaires 4Radiotherapy, Intensity-Modulated 4Platinum 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Stem Cell Transplantation × CNS × 30 days × Clear all
NCT03786783 2026-06-02

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 12 charts
CNS

Ganglioneuroblastoma

NCT06172296 2026-06-02

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 3 Recruiting
478 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡